Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anika Therapeutics (NAS:ANIK) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Anika Therapeutics Forward PE Ratio Related Terms
Anika Therapeutics Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Anika Therapeutics's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anika Therapeutics Forward PE Ratio Chart
Anika Therapeutics Annual Data
Trend
2015-12
2016-12
2017-12
2018-12
2019-12
2020-12
2021-12
Forward PE Ratio
24.75
21.98
29.41
21.88
32.68
50.25
86.96
Anika Therapeutics Quarterly Data
2015-12
2016-03
2016-06
2016-09
2016-12
2017-03
2017-06
2017-09
2017-12
2018-03
2018-06
2018-09
2018-12
2019-03
2019-06
2019-09
2019-12
2020-03
2020-06
2020-09
2020-12
2021-03
2021-06
2021-09
2021-12
2022-03
2024-03
2024-06
2024-09
Forward PE Ratio
24.75
23.75
26.88
22.78
21.98
20.62
25.91
33.90
29.41
32.05
29.07
35.46
21.88
25.13
34.13
39.22
32.68
15.87
60.98
25.32
50.25
40.65
112.36
74.07
86.96
76.34
22.68
23.47
18.62
ANIK vs SIGA, DERM, LFCR: Forward PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Anika Therapeutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anika Therapeutics Forward PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anika Therapeutics's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Anika Therapeutics's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Anika Therapeutics (ANIK) has a Forward PE Ratio of 55.27 as of Aug. 17, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Anika Therapeutics and its competitors. According to the industry distribution chart, Anika Therapeutics ranks #362 out of 409 companies in the Drug Manufacturers industry, placing it in the top 88.5%.
Is Anika Therapeutics' Forward PE Ratio too high?
Anika Therapeutics' current Forward PE Ratio is 55.27. The Drug Manufacturers industry median Forward PE Ratio is 17.64. Anika Therapeutics' value of 55.27 is 213.3% above this industry median. Based on the distribution chart, Anika Therapeutics ranks #362 out of 409 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Anika Therapeutics has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Anika Therapeutics' Forward PE Ratio compare to SIGA and DERM?
According to the Drug Manufacturers industry distribution chart, Anika Therapeutics ranks #362 out of 409 companies for Forward PE Ratio. This places Anika Therapeutics in the lower half of its industry. The industry median Forward PE Ratio is 17.64. Anika Therapeutics' value of 55.27 is 213.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 17.64, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anika Therapeutics's current Forward PE Ratio of 55.27 is 213.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Anika Therapeutics and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 17.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anika Therapeutics's current Forward PE Ratio is 55.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anika Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Anika Therapeutics (ANIK) is currently considered Modestly Overvalued. The stock's GF Value™ is $19.18, compared to a current price of $21.50 — trading 12.1% above its estimated fair value. The current Forward PE Ratio is 55.27 and 213.3% above the Drug Manufacturers industry median of 17.64. Anika Therapeutics' overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Anika Therapeutics (ANIK), the current Forward PE Ratio is 55.27 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anika Therapeutics (ANIK) Overvalued in 2026?
Based on GuruFocus' analysis, Anika Therapeutics stock appears to be overvalued.
The current stock price of $21.50 is trading 12.1% above its estimated GF Value™ of $19.18.
GuruFocus considers Anika Therapeutics to be Modestly Overvalued.
Key valuation signals for ANIK:
Forward PE Ratio: 55.27
GF Value™: $19.18 vs. price of $21.50 (12.1% above fair value)
Industry Position: 213.3% above the Drug Manufacturers median (#362 of 409)
No single metric tells the full story. See the ANIK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
58GF Score
Get the complete analysis for ANIK
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANIK has been successfully added to your 
